期刊文献+

精氨酸脱亚胺酶基因在大肠杆菌中的克隆、表达及纯化 被引量:3

Cloning,Expression and Purification of Arginine Deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli BL21(DE3)
在线阅读 下载PDF
导出
摘要 通过PCR扩增得到菌株编码ADI的arcA基因,并构建表达载体pET24a-ADI。将该载体导入大肠杆菌BL21(DE3),获得高效表达ADI基因的重组菌。对ADI诱导表达条件进行优化,结果发现宿主菌在A600达到1.0时加入0.2 mmol/L异丙基-β-D-硫代半乳糖苷(IPTG),在30℃诱导4 h酶活最高,为2.04 U/mL发酵液。经超声波破碎、HiPrep DEAE FF阴离子交换层析、SuperdexTM200凝胶过滤层析,可获得SDS-PAGE电泳纯重组精氨酸脱亚胺酶(rADI)。rADI相对分子质量大小为92 600,由两个相同亚基组成,纯化后的rADI比酶活达20.9 U/mg。 Arginine deiminase(ADI),an arginine degrading enzyme,has been studied as a potential anti-cancer agent for inhibiting arginine-auxotrophic tumors,such as melanomas and hepatocellular carcinomas(HCCs).In this study,the arcA gene that encodes ADI was cloned from P.plecoglossicida CGMCC2039 which was isolated and identified by our laboratory previously.The arcA gene was subcloned into expression vector pET24a and its product ADI was over-expressed in Escherichia coli BL21(DE3).The effects of different IPTG concentrations,induction temperatures and induction time were investigated.Under the optimal expression conditions the enzyme activity reached to 2.04 U/mL broth.The rADI was purified using DEAE Fast Flow anion exchange and SuperdexTM 200 gel filtration column chromatography.The rADI had a molecular mass of about 92.6 kDa,and comprised a homodimer of 46 kDa in the native condition.The specific activity of rADI was determined to be 20.9 U/mg at pH 6.0 and 37 ℃.
出处 《食品与生物技术学报》 CAS CSCD 北大核心 2011年第5期750-756,共7页 Journal of Food Science and Biotechnology
基金 国家自然科学基金项目(30900030) 教育部新教师基金项目(20090093120008)
关键词 精氨酸脱亚胺酶 克隆 表达 纯化 arginine deiminase cloning expression purification
  • 相关文献

参考文献21

  • 1Verhoef C, Visser O, de Man RA, et al. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns [J]. European Journal of Cancer, 2004, 40: 1530-- 1538.
  • 2El-Scrag H B, Mason A C, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States [J]. Hepatology, 2001, 33: 62--65.
  • 3El-Serag HB. Hepatocellular carcinoma: an epidemiologic view[J]. Clin Gastroenterol, 2002, 35:S72--S78.
  • 4Izzo F, Marra P, Beneduce G, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase Ⅰ/Ⅱ studies[J]. J Clin Oncol, 2004,22(10) :815--822.
  • 5Takaku H, Takase M, Miyazaki K, et al. In vivo anti tumor activity of arginine deiminase purified from Mycoplasma arginini[J], Int J Cancer, 1992, 51: 244-249.
  • 6Takaku H, Misawa S, Hayashi H, et al. Chemical modification by polyethylene glycol of the anti--tumor enzyme argi- nine deiminase from Mycoplasma arginini[J]. Jpn J Cancer Res, 1993, 84: 1195--1200.
  • 7Takaku H, Matsumoto M, Misawa S, et al. Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth inhibitory mechanism[J]. Jpn J Cancer lies, 1995, 86: 840--846.
  • 8Miyazaki K, Takaku H, Umeda M, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line[J]. Cancer Res, 1990, 50: 4522--4527.
  • 9Sugimura K, Ohno T, Fukuda S, et al. Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor [J]. Cancer Res, 1990, 50:345 349.
  • 10Sugimura K, Ohno T, Kusuyama T, et al. High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro[J]. Melanoma Res, 1992, 2: 191--196.

二级参考文献6

共引文献19

同被引文献40

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部